[KIM, Joong Kyu 김중규, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, WOO, Sung Ho 우성호, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, WOO, Sung Ho 우성호, KIM, Hak-Sung 김학성, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, WOO, Sung Ho 우성호, KIM, Hak-Sung 김학성, LEE, Joong-jae 이중재, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, WOO, Sung Ho 우성호, KIM, Hak-Sung 김학성, LEE, Joong-jae 이중재, JO, Seong-Min 조성민, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, WOO, Sung Ho 우성호, KIM, Hak-Sung 김학성, LEE, Joong-jae 이중재, JO, Seong-Min 조성민, RYOU, Jeong-Hyun 유정현, KIM, Joong Kyu 김중규, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, JUNG, Ji Eun 정지은, KIM, Sun Young 김선영, CHO, Jong Un 조종운, JUNG, Doo Hwan 정두환, MIN, Ji Young 민지영, KIM, Yong Zu 김용주, PARK, Tae Kyo 박태교, WOO, Sung Ho 우성호, KIM, Hak-Sung 김학성, LEE, Joong-jae 이중재, JO, Seong-Min 조성민, RYOU, Jeong-Hyun 유정현, KIM, Tae Yoon 김태윤] 8-26, Munpyeongseo-ro 34302 대전광역시 대덕구 문평서로 8-26, DaejeonDaedeok-guDaejeon 34302;291, Daehak-ro 34141 대전광역시 유성구 대학로 291, DaejeonYuseong-guDaejeon 34141 The present invention relates to a drug conjugate using a repebody derivative, and a preparation method thereof and, more specifically, to a repebody derivative drug conjugate (RDC) in which a drug, a toxin, a ligand, and a substance having activity such as detection marking are conjugated to repebody, which exhibits substrate specificity by connecting a leucine-rich repeat (LRR) structure originated from a variable lymphocyte receptor (VLR) as a variable region on the N-terminus of an LRR family protein having an alpha helical capping motif, and a preparation method thereof. The RDC according to the present invention is a conjugate which is combined with a compound having high substrate specificity and excellent tissue and tumor penetration that repebody provides, and biological activity. As such, the RDC has the advantages of having superior efficacy compared to the case of using repebody alone, and having specific selectivity compared to the case of using the compound alone. Due to these features, the RDC is expected to be utilized in the treatment of tumors by combining, with repebody, which specifically binds to a protein overexpressed on cancer cells, a toxin that kills cells, to thereby selectively kill only the cancer cells.

[KIM, Jun-Kyum 김준겸, CHOI, Jia 최지아, KIM, Eun-Jung 김은정, PARK, Cheol-Kyu 박철규, HAM, Seok Won 함석원, PARK, Min Gi 박민기, JEONG, Hyeon Ju 정현주, KIM, Sung Jin 김성진, MIN, Kyungim 민경임, PARK, Jong Min 박종민, CHIN, Jungwook 진정욱, CHO, Sung Jin 조성진, KIM, Jina 김진아, JUNG, Kyung Jin 정경진, KIM, Nayeon 김나연, KIM, Suhui 김수희, KWON, Sugyeong 권수경, LEE, Su-Jeong 이수정, JEONG, Minseon 정민선, AN, Hongchan 안홍찬, PARK, Jeong-Eun 박정은, KIM, Dong-Hyun 김동현, LIM, Ji-youn 임지연, MIN, Ju-sik 민주식, HWANG, Ji Sun 황지선, CHOI, Hyo-Jung 최효정, HWANG, Hayoung 황하영, KWON, Oh-Bin 권오빈, LEE, Sungwoo 이성우, KIM, Sang Bum 김상범] 593-8 Dongtangiheung-ro 18469 경기도 화성시 동탄기흥로 593-8, Gyeonggi-doHwaseong-siGyeonggi-do 18469;88 Dongnae-ro 41061 대구광역시 동구 동내로 88, DaeguDong-guDaegu 41061 The present invention relates to a substituted heterocyclic derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a stereoisomer thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating cancer comprising same as an active ingredient.

[KIM, Jun-Kyum 김준겸, CHOI, Jia 최지아, KIM, Eun-Jung 김은정, PARK, Cheol-Kyu 박철규, HAM, Seok Won 함석원, PARK, Min Gi 박민기, JEONG, Hyeon Ju 정현주, KIM, Sung Jin 김성진, MIN, Kyungim 민경임, PARK, Jong Min 박종민, CHIN, Jungwook 진정욱, CHO, Sung Jin 조성진, KIM, Jina 김진아, JUNG, Kyung Jin 정경진, KIM, Nayeon 김나연, KIM, Suhui 김수희, KWON, Sugyeong 권수경, LEE, Su-Jeong 이수정, JEONG, Minseon 정민선, AN, Hongchan 안홍찬, PARK, Jeong-Eun 박정은, KIM, Dong-Hyun 김동현, LIM, Ji-youn 임지연, MIN, Ju-sik 민주식, HWANG, Ji Sun 황지선, CHOI, Hyo-Jung 최효정, HWANG, Hayoung 황하영, KWON, Oh-Bin 권오빈, LEE, Sungwoo 이성우, KIM, Sang Bum 김상범] 593-8 Dongtangiheung-ro 18469 경기도 화성시 동탄기흥로 593-8, Gyeonggi-doHwaseong-siGyeonggi-do 18469 The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient. The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient.

[CHUNG, Chul-Woong 정철웅, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, SONG, Ho Young 송호영, PARK, Kyung Eun 박경은, KIM, Sung Min 김성민, KIM, Hyoung Rae 김형래, KIM, Yong Zu 김용주, OH, Yeong Soo 오영수, CHAE, Jeiwook 채제욱, NAM, Do-Hyun 남도현, PARK, Hyunkyu 박현규, PARK, Chang Sik 박창식, CHOI, Min Ji 최민지] 8-26, Munpyeongseo-ro 34302 대전시 대덕구 문평서로 8-26, DaejeonDaedeok-guDaejeon 34302;48, Itaewon-ro 55-gil 04348 서울시 용산구 이태원로55길 48, SeoulYongsan-guSeoul 04348 The present invention relates to: novel antibody-drug conjugates (ADC) targeting EGFRvIII; a metabolite for activating the ADCs; a method for producing the ADCs; uses of the ADCs to treat and/or prevent diseases; and uses of the ADCs to produce drugs for treating and/or preventing diseases, more specifically, hyperplasia and/or angiogenesis for example, and cancerous diseases. More specifically, the present invention relates to: an antibody-drug conjugate which includes an antibody binding to epidermal growth factor receptor variant III (EGFRvIII), or includes an antigen-binding fragment of the antibody; and a pharmaceutical composition including same. The present invention relates to: novel antibody-drug conjugates (ADC) targeting EGFRvIII; a metabolite for activating the ADCs; a method for producing the ADCs; uses of the ADCs to treat and/or prevent diseases; and uses of the ADCs to produce drugs for treating and/or preventing diseases, more specifically, hyperplasia and/or angiogenesis for example, and cancerous diseases. More specifically, the present invention relates to: an antibody-drug conjugate which includes an antibody binding to epidermal growth factor receptor variant III (EGFRvIII), or includes an antigen-binding fragment of the antibody; and a pharmaceutical composition including same.

[KIM, Jong-Won 김종원, CHOI, Hyo-Jung 최효정, KIM, Sung-Min 김성민, PARK, Yeo-reum 박여름, HWANG, Seok-Jin 황석진, CHANG, Kiho 장기호, AHN, Sung-Min 안성민] 1701-ho-1711-ho, 58, Gasan digital 1-ro, 08591 서울특별시 금천구 가산디지털1로 58, 1701호-1711호, SeoulGeumcheon-gu,Seoul 08591 The present invention relates to a fusion protein comprising GLP-1, immunoglobulin Fc, and IGF-1, and use thereof. The fusion protein of the present invention has excellent efficiency in blood-brain barrier permeability, and thus can be widely used for the effective treatment of neurological diseases.

[SONG, Ji Yoon 송지윤, CHOI, Hyo Jeong 최효정, NOH, Hyeon Jin 노현진, PARK, Young Ha 박영하, JUNG, Yi Reh 정이레] 7F, 114, Central town-ro 16506 경기도 수원시 영통구 센트럴타운로 114, 7층, Gyeonggi-doYeongtong-guSuwon-siGyeonggi-do 16506 Provided are: a recombinant microorganism expressing a VIP gene; and a composition for preventing or treating diseases that cause damage to the gastrointestinal tract, comprising the microorganism.

[KIM, Jina 김진아, CHO, Sung Jin 조성진, JEON, Yong Hyun 전용현, CHIN, Jungwook 진정욱, HWANG, Hayoung 황하영, LEE, Jae-Eon 이재언, JEONG, Minseon 정민선, LEE, Su-Jeong 이수정, AN, Hongchan 안홍찬, HWANG, Ji Sun 황지선, CHOI, Hyo-Jung 최효정, KWON, Sugyeong 권수경] 88 Dongnae-ro 41061 대구광역시 동구 동내로 88, DaeguDong-guDaegu 41061 The present invention relates to an ethene compound in a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof, which each act as an estrogen-related receptor β/γ (ERRβ/γ) inverse agonist, and a pharmaceutical composition including same as an active ingredient for prevention or treatment of cancer. The present invention relates to an ethene compound in a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof, which each act as an estrogen-related receptor β/γ (ERRβ/γ) inverse agonist, and a pharmaceutical composition including same as an active ingredient for prevention or treatment of cancer.

[SONG, Ho Young 송호영, KIM, Sung Min 김성민, KIM, Hyoung Rae 김형래, PARK, Kyung Eun 박경은, CHUNG, Chul-Woong 정철웅, PARK, Yun-Hee 박윤희, CHOI, Hyo Jung 최효정, LEE, Su In 이수인, BAEK, Juyuel 백주열, LEE, Hyeun Joung 이현정, LEE, Ju Young 이주영, OH, Jihye 오지혜, CHAE, Jeiwook 채제욱, OH, Yeong Soo 오영수, KIM, Yong Zu 김용주] 8-26, Munpyeongseo-ro 34302 대전시 대덕구 문평서로 8-26, DaejeonDaedeok-guDaejeon 34302 The present invention relates to a pyrrolobenzodiazepine precursor and a ligand-linker conjugate compound thereof, a composition containing the same, and, in particular, a therapeutic use thereof as an anti-cancer agent. The present invention is industrially useful in that it is possible to target proliferative diseases such as cancer, perform a specific treatment, maximize medicinal effects, and minimize the occurrence of side effects, since the compound itself is very stable, has excellent stability in plasma, and has advantages in terms of toxicity manifestation.